Biosimilar SB15 versus reference aflibercept in neovascular age-related macular degeneration: 1-year and switching results of a phase 3 clinical trial.
Se Joon WooSriniVas R SaddaMario BradvicaAttila VajasMin SagongJan ErnestJan StudničkaMiroslav VeithEdward WylegalaSunil PatelCheolmin YunMichal OrskiSergei AstakhovEdit Tóth-MolnárAdrienne CsutakLajos EnyediWooree ChoiInkyung OhHyerin JangPublished in: BMJ open ophthalmology (2023)
Efficacy, safety, PK and immunogenicity were comparable between SB15 and AFL and between switched and non-switched participants.